Details of the Drug

General Information of Drug (ID: DM4CWNN)

Drug Name

AVT02

Synonyms

adalimumab biosimilar

Indication

Disease Entry	ICD 11	Status	REF
Plaque psoriasis	EA90.0	Phase 3	[1]

Drug Type

Antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Not Available	[2]

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Plaque psoriasis

ICD Disease Classification

EA90.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tumor necrosis factor (TNF)	DTT	TNF	8.51E-01	0.05	0.27

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03849404) A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira? in Patients With Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS). U.S.National Institutes of Health.
2	AVT02: An Adalimumab Biosimilar. Clin Drug Investig. 2022 Oct;42(10):875-878.